Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
Could This Be the 'Ozempic of Alcohol'? Existing Medication Shows Promise - Featured image
Health

Could This Be the 'Ozempic of Alcohol'? Existing Medication Shows Promise

An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.

Shotlee·December 8, 2025·Updated Jan 27, 2026·3 min read
Share:

Could This Be the 'Ozempic of Alcohol'? Existing Medication Shows Promise

A readily available and inexpensive pill is being touted as the "Ozempic of alcohol" because of its potential to decrease cravings for alcohol, similar to how GLP-1 medications reduce food cravings.

Naltrexone, costing approximately $1.60 per pill when purchased in bulk, functions by obstructing opioid receptors in the brain, thereby lessening the dopamine-reward effect individuals experience from drinking, which in turn reduces the urge for alcohol.

In essence, alcohol ceases to provide the same level of satisfaction, which aids in reducing the desire for it.

Since 1994, the US Food and Drug Administration has given its approval to Naltrexone for the treatment of alcohol use disorder, and since 1984 for opiate dependence.

Nearly 28 million individuals in the United States grapple with alcohol use disorder.

The Centers for Disease Control and Prevention estimates that 17% of adult Americans engage in binge drinking, a pattern more prevalent among men. Heavy drinking can take a toll on finances, health and lead to tragic outcomes. Health tracking apps like Shotlee can help monitor alcohol consumption and related health data.

Research indicates that among users who took naltrexone, a prescription medication, an hour prior to drinking, 80% experienced a significant reduction or complete elimination of their alcohol consumption.

Besides the pill form, Oar Health markets naltrexone as a mint under the name Clutch. For individuals who struggle with adherence, the drug is also available as a once-a-month injection.

Nausea and headaches have been reported as side effects of naltrexone, but specialists note that the nausea tends to diminish as patients become accustomed to the treatment.

This characteristic differentiates naltrexone from acamprosate, another approved medication for alcohol use disorder, which necessitates monitoring by a healthcare professional due to potential side effects like suicidal thoughts and depression.

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Become aBeta Tester

Furthermore, unlike disulfiram, another drug approved for treating alcohol use disorder that induces unpleasant and potentially life-threatening side effects when combined with alcohol, naltrexone does not mandate strict abstinence from alcohol.

For many individuals, naltrexone has proven to be a transformative solution.

Military veteran and podcast host Jesse Carrajat stated, "The first time I took naltrexone, I remember not just wanting to impulsively turn to alcohol. It was gone... For the first time in my life, when things got hard, I wasn't turning to alcohol."

His personal experience is echoed in the comments shared on his TikTok account.

One user commented, "I had tried so many times to detox on my own, and it did not work. Naltrexone saved me."

Another user stated, "Worked instantly for me 4 months alcohol free."

Meanwhile, a Reddit user who had struggled with alcohol since his teenage years and gradually saw his dependence affect his quality of life said that his first dose of naltrexone resulted in an immediate reframe of his drinking habits.

He explained, "The first time I took it, I still drank, arguably quite a lot, but I didn't spiral. I didn't lose control... I left the party at a decent time, 1 AM, because I was tired. I woke up the next morning feeling surprisingly fresh... That alone felt like a miracle."

The subsequent year, the man exclusively used naltrexone before significant occasions and high-risk situations, but by 2025, he committed to taking the pill each time he consumed alcohol.

He declared, "Now? I barely think about drinking... The Friday craving is gone... I can have a beer at a bar with friends and stop after one or two. And if I don't drink, I don't feel deprived, I just feel normal."

Original source: New York Post

View original article →
#naltrexone#alcohol use disorder#Ozempic of alcohol#alcohol cravings#addiction treatment
  1. Home
  2. Blog
  3. Could This Be the 'Ozempic of Alcohol'? Existing Medication Shows Promise

Related Articles

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds
GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report
Metabolic Health

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report

Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community